Skip to content

Virtual Reality-based Interactive Treadmill Gait Training System for Parkinson's Disease

Virtual Reality-based Interactive Treadmill Gait Training System for Parkinson's Disease: A Randomized, Double-blind, Sham-controlled Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03686462
Enrollment
22
Registered
2018-09-27
Start date
2018-10-15
Completion date
2019-11-11
Last updated
2019-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Virtual Reality; Rehabilitation; Parkinson's Disease

Brief summary

Virtual-reality-based interactive treadmill system will be applied to the Parkinsons' disease patients who can walk (Hoehn and Yahr stage 2 to 4). Subjects will be randomly allocated to either VR-based treadmill training group or treadmill training without VR-based interaction. The training will be provided for 3 sessions (30min/session)/week for 4weeks, the total of 12 sessions. The outcomes will be measured at baseline, immediately after the completion of the intervention and 1 month after the intervention.

Interventions

DEVICEVirtual reality-based interactive treadmill training

During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.

DEVICETreadmill training without VR-based interaction

Treadmill training without VR-based interaction

Sponsors

Ministry of Trade, Industry & Energy(MOTIE, Korea)
CollaboratorUNKNOWN
Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* definite or probable idiopathic Parkinson disease patient * age from 18 to 80 years old * H&Y stage 2 to 4 and who can walk 10 meter independently regardless of the use of gait aids

Exclusion criteria

* unstable medical conditions * cognitive impairments which interfere with participation in virtual-reality based training * hemispatial neglect, visual disturbance, apraxia * other pre-existing disease involving the central nervous system (e.g. stroke, brain tumor) * requiring the continuous manual assist with touch during the treadmill training * can not give a consent

Design outcomes

Primary

MeasureTime frameDescription
Unified Parkinson's disease rating scale (UPDRS) part IIIChange from Baseline UPDRS III at 4 weeksmotor domain of UPDRS, range: 0 (best) -52 (worst)

Secondary

MeasureTime frameDescription
Freezing of gait questionnaireChange from Baseline Freezing of gait questionnaire at 4 weeksrange: 0 (best) -24 (worst)
Fear of fallingChange from Baseline fear of falling at 4 weeksNumeric rating scale ranging from 0 (no fear) to 10 (most severe fear of falling).
Total number of falls during the recent 1 monthChange from Baseline total number of falls at 4 weeks
User satisfaction evaluation questionnaireAt 4weeks (after the completion of whole interventions)
Berg balance scale (BBS)Change from Baseline BBS at 4 weeksrange: 0 (worst) -52 (best)
Gait parameters from gait analysisChange from Baseline gait parameters at 4 weeksgait speed, step length, cadence
Unified Parkinson's disease rating scale (UPDRS) part IIIChange from Baseline UPDRS III at 8 weeksmotor domain of UPDRS, range: 0 (best) -52 (worst)
10 meter walk test (10MWT)Change from Baseline 10MWT at 4 weeksgait speed (m/s)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026